Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM NASDAQ:ALXO NASDAQ:RANI NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$8.40-0.1%$9.02$2.51▼$39.95$6.42M0.988,721 shs3,418 shsALXOALX Oncology$0.53-2.6%$0.49$0.40▼$6.38$28.83M1.11654,166 shs215,862 shsRANIRani Therapeutics$0.53+6.1%$0.55$0.39▼$3.75$33.63M-0.024.56 million shs1.31 million shsTPSTTempest Therapeutics$7.76+20.7%$6.92$5.33▼$28.34$23.70M-1.9563,238 shs330,192 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-0.18%-9.19%-5.99%-8.10%-76.16%ALXOALX Oncology-2.56%+3.87%+14.97%-2.86%-91.53%RANIRani Therapeutics+6.10%+28.01%+4.31%-52.50%-81.33%TPSTTempest Therapeutics+20.68%+23.17%+8.53%0.00%-65.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech0.9697 of 5 stars3.50.00.00.00.60.00.0ALXOALX Oncology3.8518 of 5 stars3.43.00.00.03.84.21.3RANIRani Therapeutics2.494 of 5 stars3.51.00.00.03.81.70.6TPSTTempest Therapeutics2.3404 of 5 stars3.34.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.003,173.81% UpsideALXOALX Oncology 2.71Moderate Buy$3.30527.14% UpsideRANIRani Therapeutics 3.00Buy$7.331,278.45% UpsideTPSTTempest Therapeutics 2.50Moderate Buy$30.00286.60% UpsideCurrent Analyst Ratings BreakdownLatest AIM, RANI, ALXO, and TPST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025ALXOALX OncologyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/16/2025RANIRani TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.005/9/2025ALXOALX OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.00(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K43.96N/AN/A$0.20 per share42.00ALXOALX OncologyN/AN/AN/AN/A$2.14 per shareN/ARANIRani Therapeutics$1.20M28.02N/AN/A$0.06 per share8.87TPSTTempest TherapeuticsN/AN/AN/AN/A$5.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/AALXOALX Oncology-$134.85M-$2.47N/AN/AN/AN/A-104.43%-77.74%8/14/2025 (Estimated)RANIRani Therapeutics-$30.02M-$0.99N/AN/AN/AN/A-1,258.76%-80.52%8/5/2025 (Estimated)TPSTTempest Therapeutics-$41.84M-$17.98N/AN/AN/AN/A-305.51%-119.74%8/14/2025 (Estimated)Latest AIM, RANI, ALXO, and TPST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALXOALX Oncology-$0.46N/AN/AN/AN/AN/A8/14/2025Q2 2025TPSTTempest Therapeutics-$3.23N/AN/AN/AN/AN/A8/5/2025Q2 2025RANIRani Therapeutics-$0.19N/AN/AN/AN/AN/A5/13/2025Q1 2025RANIRani Therapeutics-$0.22-$0.22N/A-$0.22N/A$0.20 million5/13/2025Q1 2025TPSTTempest Therapeutics-$3.71-$3.16+$0.55-$3.16N/AN/A5/8/2025Q1 2025ALXOALX Oncology-$0.47-$0.58-$0.11-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AALXOALX OncologyN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75ALXOALX Oncology0.095.475.47RANIRani Therapeutics2.750.880.88TPSTTempest TherapeuticsN/A1.701.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%ALXOALX Oncology97.97%RANIRani Therapeutics30.19%TPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%ALXOALX Oncology21.00%RANIRani Therapeutics45.08%TPSTTempest Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableALXOALX Oncology4053.40 million42.18 millionOptionableRANIRani Therapeutics11063.21 million34.71 millionOptionableTPSTTempest Therapeutics203.68 million3.51 millionOptionableAIM, RANI, ALXO, and TPST HeadlinesRecent News About These CompaniesTempest Therapeutics’ Promising Advances in Liver Cancer TreatmentJuly 3, 2025 | tipranks.comTempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - NasdaqJuly 2, 2025 | nasdaq.comTempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in ChinaJune 30, 2025 | quiverquant.comQTempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in ChinaJune 30, 2025 | globenewswire.comTPST - Tempest Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMTPST Tempest Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comTempest announces $4.6 million registered direct offering of common stock; shares decline over 13%June 11, 2025 | msn.comTempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | quiverquant.comQTempest Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | globenewswire.comTempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic AlternativesJune 7, 2025 | marketwatch.comTempest Therapeutics Shares Up, Executive Team Enters Into Consulting AgreementsJune 7, 2025 | marketwatch.comTPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer TherapyJune 6, 2025 | zacks.comTempest Therapeutics stock rises on EMA Orphan Drug DesignationJune 5, 2025 | au.investing.comTempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCCJune 5, 2025 | globenewswire.comTempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finance.yahoo.comTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comTempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual MeetingApril 28, 2025 | globenewswire.comDual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous PolyposisApril 25, 2025 | empr.comECash-strapped Bay Area biotech company lays off all but 5 employeesApril 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportBy Jeffrey Neal Johnson | July 13, 2025View 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportAlphabet: Technical Momentum Is Starting to TurnBy Ryan Hasson | July 10, 2025View Alphabet: Technical Momentum Is Starting to TurnAnalysts Bet Big on Uber Stock's Expansion in Autonomous DrivingBy Gabriel Osorio-Mazilli | July 14, 2025View Analysts Bet Big on Uber Stock's Expansion in Autonomous DrivingQuantumScape Soars 30%: What Drove the Next-Gen EV Stock's RallyBy Leo Miller | June 27, 2025View QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's RallyA Huge Bet on Uranium: Why Traders Are Piling Into the URNM ETFBy Jeffrey Neal Johnson | July 24, 2025View A Huge Bet on Uranium: Why Traders Are Piling Into the URNM ETFAIM, RANI, ALXO, and TPST Company DescriptionsAIM ImmunoTech NYSE:AIM$8.40 -0.01 (-0.12%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$8.43 +0.03 (+0.36%) As of 07/25/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.ALX Oncology NASDAQ:ALXO$0.53 -0.01 (-2.56%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$0.53 +0.01 (+1.29%) As of 07/25/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Rani Therapeutics NASDAQ:RANI$0.53 +0.03 (+6.10%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$0.52 -0.01 (-1.69%) As of 07/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Tempest Therapeutics NASDAQ:TPST$7.76 +1.33 (+20.68%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$7.82 +0.06 (+0.82%) As of 07/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
